Kazia Therapeutics’ Sovargen doses first patient in Phase 1b/2a
Kazia Therapeutics announced that Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders.
Story updates
11:30:50 AM UTC
SquawkNews
KZIA KZIA - Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
11:31:31 AM UTC
SquawkNews
Kazia said Sovargen dosed the first patient in a Phase 1b/2a trial of paxalisib for FCD T2 and TSC, triggering a $2M payment to Kazia under their 2024 license. Kazia remains eligible for up to $17M in additional milestones, plus sublicensing revenues and royalties.Material DetailsContext by AI Anal…